Dermata investor holds 17.3% stake in common stock

Dermata Therapeutics, Inc. investor update: Gerald T. Proehl filed Amendment No. 10 to his beneficial ownership report, stating that he may be deemed to beneficially own 694,687 shares of Dermata common stock.

Rhea-AI Filing Summary

Dermata Therapeutics, Inc. investor update: Gerald T. Proehl filed Amendment No. 10 to his beneficial ownership report, stating that he may be deemed to beneficially own 694,687 shares of Dermata common stock. This represents 17.3% of the company’s outstanding common stock as of a recent share count.

The filing explains that his holdings include shares and options held directly, shares and warrants held through Proehl Investment Ventures LLC, and shares held by certain trusts for which he serves as trustee. The amendment also notes that there have been no purchases or sales of Dermata common stock or related convertible securities by him or entities he controls since a prior amendment earlier in 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much of Dermata Therapeutics (DRMA) does Gerald T. Proehl currently beneficially own?

Gerald T. Proehl reports beneficial ownership of 694,687 Dermata common shares, representing 17.3% of the outstanding stock. This percentage is based on 4,022,143 common shares outstanding as of February 23, 2026, according to information he obtained from the company.

What securities make up Gerald T. Proehl’s 694,687-share beneficial ownership in DRMA?

His reported 694,687-share stake includes shares and options held directly, shares and warrants held by Proehl Investment Ventures LLC, and shares held by certain trusts. He serves as trustee of these trusts, which collectively hold 612,828 Dermata common shares attributed to his beneficial ownership.

Has Gerald T. Proehl traded Dermata Therapeutics (DRMA) stock recently according to Amendment No. 10?

The amendment states there have been no purchases or sales of Dermata common stock, or securities convertible into or exchangeable for common stock, by Mr. Proehl or entities he controls since Amendment No. 8 filed on January 8, 2026. His reported position is therefore unchanged in trading terms.

Which entities and instruments related to DRMA are attributed to Gerald T. Proehl’s beneficial ownership?

The filing attributes to him directly held shares and options, holdings of Proehl Investment Ventures LLC, and shares held by certain trusts where he is trustee. It also counts warrants exercisable within sixty days, while excluding unvested options and non-exercisable warrants outside that 60-day window.

What Dermata Therapeutics (DRMA) share count underlies the 17.3% ownership figure for Gerald T. Proehl?

The 17.3% ownership figure is calculated using 4,022,143 Dermata common shares outstanding as of February 23, 2026. That share count comes from information Mr. Proehl obtained from Dermata and is used to determine his percentage of the company’s equity.

What is the main purpose of Gerald T. Proehl’s Amendment No. 10 related to Dermata Therapeutics (DRMA)?

Amendment No. 10 updates his Schedule 13D disclosures regarding beneficial ownership of Dermata common stock. It restates his aggregate 694,687-share position, confirms his 17.3% stake based on the latest outstanding share figure, and notes that no new trades have occurred since an earlier 2026 amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 07:56 PM EST Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 10)

Dermata Therapeutics, Inc.

(Name of Issuer)

Common Stock, Par Value $0.0001 Per Share.

(Title of Class of Securities)

249845504

(CUSIP Number)

Gerald T. Proehl
President and Chief Executive Officer,, 3525 Del Mar Heights Rd., #322
San Diego, CA, 92130
(973) 701-2431

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/19/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 249845504

1

Name of reporting person

PROEHL GERALD T

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 694,687.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 694,687.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

694,687.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

17.3 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 5 for additional information.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, Par Value $0.0001 Per Share.
(b)	Name of Issuer: Dermata Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3525 Del Mar Heights Rd., #322, San Diego, CALIFORNIA , 92130.
Item 1 Comment: This Amendment No. 10 (this "Amendment") amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on August 27, 2021, as amended on April 25, 2022, January 13, 2023, March 30, 2023, January 23, 2025, February 13, 2025, April 3, 2025, April 7, 2025, January 8, 2026, and January 29, 2026 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Schedule 13D and the information set forth in or incorporated by reference in Item 2 and Item 3 of the Schedule 13D is hereby incorporated by reference in its entirety into this Item 5. As of the date hereof, Mr. Proehl may be deemed to beneficially own an aggregate of 694,687 shares of Common Stock reported herein as follows: (i) 24 shares of Common Stock and stock options to purchase 1,874 shares of Common Stock held directly by Mr. Proehl; (ii) 79,950 shares of Common Stock and 11 shares of Common Stock underlying warrants that are exercisable within sixty (60) days of the date hereof held by Proehl Investment Ventures LLC ("PIV"); and (iii) 612,828 shares of Common Stock held in the aggregate by certain trusts (the "Trusts") for which Mr. Proehl is trustee. Mr. Proehl's reported ownership excludes (i) 40,959 shares of Common Stock underlying stock options held by Mr. Proehl that will not vest as to such shares of Common Stock within sixty (60) days of the date hereof; (ii) 1,059,132 shares of Common Stock underlying warrants that are not exercisable within sixty (60) days of the date hereof. As a result of the foregoing, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Proehl may be deemed to beneficially own 17.3% of the Common Stock of the Issuer outstanding as of the date hereof (based on 4,022,143 shares of Common Stock outstanding as of February 23, 2026 based on information obtained from the Issuer).
(b)	As of the date hereof, Mr. Proehl may be deemed to be the beneficial owner of an aggregate of 694,687 shares of Common stock, all of which he has sole voting and dispositive power.
(c)	Since Amendment No. 8 to this Schedule 13D (filed on January 8, 2026), there were no purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Person or any person or entity for which the Reporting Person possesses voting or dispositive control over the securities thereof.
(d)	None.
(e)	None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PROEHL GERALD T

Signature:	/s/ Gerald T. Proehl
Name/Title:	Gerald T. Proehl
Date:	02/23/2026